Companies
Gevo
the ATJ-30 project at Richardton, North Dakota pairs ethanol-to-jet with Class VI carbon sequestration, backed by a portfolio of more than 550 patents.
- Country
- United States
- Ticker
- NASDAQ: GEVO
ASTM D7566
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| biofuels-bioenergy | ✓ | ✓ | ✓ | ✓ |
| platform-chemicals | ✓ | ✓ | — | ✓ |
Regulatorsepareachademeferc
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Gevo is seeking project-level private capital financing and has secured a preliminary agreement for co-investment from Ara Energy for the ATJ-30 project expansion. | investors.gevo.com · globenewswire.com |
| Capacity | Targeting approximately 75 million gallons of annual low-carbon ethanol capacity at Gevo North Dakota starting in 2027, with expansion plans to double capacity to approximately 150 million gallons per year of low-carbon ethanol. | gevo.com · investors.gevo.com |
| Certification | Gevo North Dakota's CCS asset and well is certified by Puro.Earth as a thousand-year permanence well and carries an 'A' rating from BeZero Carbon. | gevo.com · investors.gevo.com |
| Regulatory approval | Gevo withdrew its loan guarantee application with the U.S. Department of Energy for the ATJ-30 project in April 2026. | investors.gevo.com · globenewswire.com |
| Production site | Gevo North Dakota (formerly Red Trail Energy) in Richardton, North Dakota. | gevo.com |
| Revenue | $47 million for the second quarter of 2026. | last10k.com · sec.gov |
Independent sources: globenewswire.com · last10k.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Advanced biofuels (SAF, renewable diesel & biomethane) | biofuels-bioenergy | Medium | → |
| Biosynthetic butanol, isobutanol and bio-C4 platforms | platform-chemicals | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.